DSSG Group: Gynaecological

Recurrent endometrial cancer; recurrent, high-grade serous epithelial ovarian, fallopian tube, and primary peritoneal cancers; or recurrent cervical cancers

This study is designed to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of IMGN151

Primary advanced or returned Endometrial cancer whose mismatch repair system is working normally and who are starting their first maintenance treatment.

The trial is testing a new combination of treatments for people with advanced or recurring Endometrial Cancer whose cancer has a “normal” mismatch-repair system (so-called “mismatch repair proficient” or pMMR).
Specifically, researchers want to see if using a combination of two drugs — Sacituzumab Tirumotecan (sometimes “sac-TMT”) plus Pembrolizumab — works better than giving pembrolizumab alone.

Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6

The purpose of the study is to assess the efficacy of TORL-1-23 administered as monotherapy in women with advanced, platinum-resistant ovarian cancer whose tumors express the claudin-6 (CLDN6) biomarker. The study will also evaluate the overall safety and tolerability of TORL-1-23 and its potential therapeutic effects in this patient population

Vulvar Cancer

This research aims to understand the long-term impact of vulvar cancer and its treatments on various aspects of a woman’s life, including physical health, emotional well-being, and sexual functioning.

Vulvar Cancer

To examine the feasibility, safety and effect of autologous fat grafting (AFG) in the treatment of chronic vulval symptoms following radiotherapy.

Recurrent (previously treated) low grade serous ovarian cancer (LGSOC) who have progressed on a prior platinum-based therapy

The purpose of the study is to assess how avutometinib plus defactinib compares to the standard
treatments for LGSOC. The study will measure effectiveness, including overall response rate (how well the
combination reduces tumor size) and safety. The study will also include quality of life assessments by the
patient.

Endometrial Cancer

The goal of the study is to learn if people who receive MK-2870 (sacituzumab tirumotecan) live longer overall and without the cancer getting worse compared to people who receive chemotherapy.

p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma.

When we say someone has p53 wildtype cancer, it means their guardian (p53) is working as it should. It’s like having a strong and reliable guardian who can keep an eye on things and prevent trouble (like stopping cells from growing out of control).

So, in simple terms, p53 wildtype cancer means the guardian in the body is doing its job properly, but still, cancer has somehow developed.

The purpose of this study is to evaluate the efficacy and safety of Selinexor as a maintenance treatment in patients with p53 wildtype endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response Evaluation Criteria in Solid Tumours version 1.1 [RECIST v 1.1]) after completing at least 12 weeks of platinum-based therapy. A total of 220 participants will be enrolled in the study and randomised in a 1:1 ratio to maintenance therapy with either Selinexor or placebo.

First platinum sensitive relapsed ovarian cancer

Prospective Study of HE4 serum Level in Patients with First Relapsed Ovarian Cancer. Improving the prediction of surgical outcome at secondary cytoreduction in patients with ovarian cancer. This study aims to improve upon the contemporary AGO score by including additional clinical variables like circulating HE4 and CA125 levels to predict surgical outcome at secondary cytoreduction.